HUMAN ANTI RANIBIZUMAB

Human Anti-Ranibizumab Antibody, clone AbD29858_hIgG1 is a non-inhibitory, anti-idiotypic antibody in full immunoglobulin format that specifically recognizes the monoclonal antibody drug ranibizumab and ranibizumab when in complex with recombinant human vascular endothelial growth factor A (VEGF-A). It does not recognize free human VEGF-A or bevacizumab. This antibody can be used to measure levels of free ranibizumab and biosimilars in patient samples.Clone AbD29858_hIgG1 in full immunoglobulin format can be used to develop a pharmacokinetic (PK) antigen capture format assay to measure free ranibizumab that has been captured via immobilized VEGF-A.Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.View a summary of all anti-ranibizumab antibodies